Kimyon, G. Et Al. 2021. Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data. Clinical and Experimental Rheumatology , vol.39, no.4 , 852-858.

Kimyon, G., KALYONCU, U., KİRAZ, S., Bes, C., COŞKUN, N. F., YAĞIZ, B., ... KÜÇÜKŞAHİN, O.(2021). Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data. Clinical and Experimental Rheumatology , vol.39, no.4, 852-858.

Kimyon, G. Et Al. "Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data," Clinical and Experimental Rheumatology , vol.39, no.4, 852-858, 2021

Kimyon, G. Et Al. "Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data." Clinical and Experimental Rheumatology , vol.39, no.4, pp.852-858, 2021

Kimyon, G. Et Al. (2021) . "Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data." Clinical and Experimental Rheumatology , vol.39, no.4, pp.852-858.

@article{article, author={G. Kimyon Et Al. }, title={Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data}, journal={Clinical and Experimental Rheumatology}, year=2021, pages={852-858} }